ISSN 2147-9720 | E-ISSN 2148-4279
Case Report
Catastrophic antiphospholipid syndrome treated with rituximab: A case report
1 Division of Rheumatology, Department of Internal Medicine, Süleyman Demirel University School of Medicine, Isparta, Turkey  
2 Department of Pathology, Süleyman Demirel University School of Medicine, Isparta, Turkey  
Eur J Rheumatol 2017; 4: 145-147
DOI: 10.5152/eurjrheum.2017.160073
This article was viewed 109 times, downloaded 109 times

Key Words: Antiphospholipid syndrome, plasmapheresis, rituximab, skin necrosis
Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a rare and fatal condition that is characterized by diffuse venous and/or arterial thromboembolism within a short period of time and histopathological confirmation of small-vessel occlusion in at least one organ or tissue in the presence of positive antiphospholipid antibodies. Here we report the case of a 19-year-old woman with CAPS. During the first week of her hospitalization, she was diagnosed with CAPS on the basis of skin necrosis, pulmonary artery thrombosis, cerebral venous sinus thrombosis, and positive lupus anticoagulant. She was treated with corticosteroids, intravenous immunoglobulins, plasmapheresis, and anticoagulants. Forty days after the onset of CAPS, cutaneous lesions were recurred during skin surgery. She required a high dose of corticosteroids, intravenous immunoglobulins, and rituximab. No further thrombotic events occurred. Rituximab may be an effective treatment option for patients with CAPS.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2017 Medical Research and Education Association | Latest Update: 09.06.2017